Baclofen and gastroesophageal reflux disease: seeing the forest through the trees. Issue 3 (March 2018)

• Record Type: Journal Article
• Authors: Clarke, John O.; Fernandez‐Becker, Nielsen Q.; Regalia, Kirsten A.; Triadafilopoulos, George
• Is Part Of: Clinical and translational gastroenterology. Volume 9:Issue 3(2018)
• Publication Date: 2018-03
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology; Gastrointestinal Diseases; Liver Diseases; Intestines -- Diseases; Stomach -- Diseases; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; 616.33
• DOI: 10.1038/s41424-018-0010-y
• Languages: English
• ISSNs: 2155-384X

Abstract

Abstract : N/A: Baclofen has been shown to decrease reflux events and increase lower esophageal sphincter pressure, yet has never established a clear role in the treatment of gastroesophageal reflux disease (GERD). Lei and colleagues have shown in a recent elegant study that baclofen reduces the frequency and initiation of secondary peristalsis and heightens esophageal sensitivity to capsaicin‐mediated stimulation. These findings may help explain both the benefit of baclofen in conditions such as rumination and supragastric belching, as well as the apparent lack of benefit of baclofen and other GABAB agonists in long‐term treatment of GERD.